Dr. Jai Patel, Associate VP, Translational Research, Director, Cancer Pharmacology & Pharmacogenomics, Atrium Health Levine Cancer, Associate Director and Dr. Laila Mnayer, Director, Molecular Pathology & Cytogenetics, Hartford Hospital, Hartfort, CT.
In this workshop, first Dr. Patel will educate about the relevance to analyzing the DPYD gene for AMP-recommended mutations, causing some cancer patients to experience severe, potentially fatal toxicity when treated with standard doses of fluoropyrimidine chemotherapies. Then, Dr. Mnayer will share how the implementation of two targeted panels for NSCLC and AML, in addition to methylation panels for MGMT and MLH1, provide results within 48-72 hours and have significantly improved the workflow in their Molecular Pathology Laboratory.
